Iterum Therapeutics (ITRM) Change in Account Payables (2017 - 2022)
Historic Change in Account Payables for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $1.5 million.
- Iterum Therapeutics' Change in Account Payables rose 15605.31% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.9 million, marking a year-over-year increase of 290793.65%. This contributed to the annual value of -$4.7 million for FY2024, which is 31345.03% down from last year.
- Latest data reveals that Iterum Therapeutics reported Change in Account Payables of $1.5 million as of Q4 2022, which was up 15605.31% from $443000.0 recorded in Q3 2022.
- Iterum Therapeutics' Change in Account Payables' 5-year high stood at $4.6 million during Q2 2018, with a 5-year trough of -$9.2 million in Q1 2020.
- For the 5-year period, Iterum Therapeutics' Change in Account Payables averaged around -$20900.0, with its median value being $432500.0 (2018).
- In the last 5 years, Iterum Therapeutics' Change in Account Payables soared by 40592.42% in 2019 and then plummeted by 56232.69% in 2021.
- Over the past 5 years, Iterum Therapeutics' Change in Account Payables (Quarter) stood at $1.3 million in 2018, then fell by 26.12% to $959000.0 in 2019, then plummeted by 286.86% to -$1.8 million in 2020, then skyrocketed by 133.65% to $603000.0 in 2021, then soared by 156.05% to $1.5 million in 2022.
- Its Change in Account Payables was $1.5 million in Q4 2022, compared to $443000.0 in Q3 2022 and $103000.0 in Q2 2022.